Medicus Pharma Ltd.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
MDCX$1.87+2.2%Stored close · as of Nov 6, 2026
Contents
Item 1. Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Six months ended June 30, | |||
|---|---|---|---|
| 2025 · 2024 | |||
| Cash flows from operating activities: | |||
| Net loss for the period | $(11,278,492) | $(5,340,217) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Stock-based compensation expense | 229,725 | 621,395 | |
| Change in operating lease right-of-use assets | 47,572 | 43,644 | |
| Change in fair value of Debentures | 200,000 | - | |
| Costs to issue Debentures | 111,725 | - | |
| Non-cash interest expense | - | 97,270 | |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses | (113,201) | 106,455 | |
| Deferred issuance costs | - | (280,712) | |
| Accounts payable | 404,670 | 655,242 | |
| Accrued expenses and other current liabilities | 1,065,475 | 214,697 | |
| Operating lease liability | (56,113) | (40,563) | |
| Related party payable | (21,186) | (30,850) | |
| Net cash used in operating activities | (9,409,825) | (3,953,639) | |
| Cash flows from financing activities: | |||
| Net proceeds from issuance of common shares and warrants | 9,790,015 | 5,470,000 | |
| Proceeds from issuance of Debentures | 4,500,000 | - | |
| Proceeds from issuance of convertible notes | - | 5,172,500 | |
| Proceeds from exercise of warrants | 977,398 | - | |
| Costs to issue Debentures | (54,582) | - | |
| Cash paid for financing costs in connection with SEPA | (297,783) | - | |
| Net cash provided by financing activities | 14,915,048 | 10,642,500 | |
| Net increase in cash and cash equivalents during the period | 5,505,223 | 6,688,861 | |
| Cash and cash equivalents, beginning of the year | 4,164,323 | 1,719,338 | |
| Cash and cash equivalents, end of the period | 9,669,546 | 8,408,199 | |
| Supplemental disclosure of non-cash investing and financing activities | |||
| Right-of-use assets obtained in exchange for lease liabilities | $ | - | 356,805 |
| Issuance costs included in accounts payable | $271,618 | - | |
| Deferred issuance costs on issued shares related to SEPA | $300,000 | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.